Company profile for Rona Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Founded in 2021 and Stella SHI, CEO and co-founder, Rona Therapeutics aims to establish innovative RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. Its RNA medicines are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems. The company is building faci...
Founded in 2021 and Stella SHI, CEO and co-founder, Rona Therapeutics aims to establish innovative RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. Its RNA medicines are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems. The company is building facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Room 1308, Caliun Road, Shanghai
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

Global ChemShow

Not Confirmed

envelop Contact Supplier

Global ChemShow

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/drug-approval/rona-submits-ind-for-galnac-conjugated-sirna-targeting-obesity-17801

INDPHARMAPOST
16 Sep 2025

https://www.expresspharma.in/rona-therapeutics-announces-ind-filing-of-rn3161-for-obesity/

#N/A
16 Sep 2025

https://www.prnewswire.com/news-releases/rona-therapeutics-announces-ind-filing-of-rn3161-a-highly-potent-and-durable-inhbe-sirna-for-obesity-302555712.html

PR NEWSWIRE
15 Sep 2025

https://www.prnewswire.com/news-releases/rona-therapeutics-announces-breakthrough-data-on-potential-annual-dosing-rnai-therapy-rn026-targeting-lipoproteina-in-the-national-lipid-association-nla-scientific-sessions-2025-302467821.html

PR NEWSWIRE
28 May 2025

https://www.prnewswire.com/news-releases/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension-302432290.html

PR NEWSWIRE
21 Apr 2025

https://www.prnewswire.com/news-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia-302402731.html

PR NEWSWIRE
17 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty